![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds from the round will fuel the rapid development of next generation of genetic nanomedicines using the polyNaut® platform, expand the scientific and management teams and establish industry-leading laboratory facilities.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: SomaServe
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 13, 2023